Clinical Trials

10 results for Bladder Cancer

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

  • Condition: Bladder Cancer
  • Study ID: NCT02625961
View Trial

PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU16-243

  • Condition: Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Durvalumab, Radiation: External Beam Radiotherapy (EBRT), Biological: Bacillus Calmette-Guérin (BCG)
  • Study ID: NCT03317158
View Trial

Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Pembrolizumab (MK-3475)
  • Study ID: NCT03504163
View Trial

Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study

  • Condition: Superficial Bladder Cancer
  • Intervention: Drug: abnobaVISCUM 900, Drug: Mitomycin C
  • Study ID: NCT02106572
View Trial

Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma

  • Condition: Bladder Cancer
  • Intervention: Drug: BCG instillation therapy, Drug: Sequential BCG and EMDA mitomycin C
  • Study ID: NCT03664869
View Trial

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

  • Condition: Bladder Urothelial Carcinoma In Situ, High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Infiltrating Bladder Mixed Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
  • Study ID: NCT04164082
View Trial

A Phase II Clinical Study of Intravesical Photodynamic Therapy in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Or Patients Who Are Intolerant to BCG Therapy ("Study").

  • Condition: Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
  • Intervention: Combination Product: TLD-1433 Bladder infusion and Photodynamic Therapy
  • Study ID: NCT03945162
View Trial

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC

  • Condition: Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
  • Study ID: NCT05375903
View Trial

A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)

  • Condition: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
  • Study ID: NCT06111235
View Trial

Phase II Trial of Intravesical Gemcitabine in Patients With Nonmuscle Invasive Bladder Cancer With or Without Prior Bacillus Calmette-Guérin Therapy

  • Condition: Urinary Bladder Cancer
  • Study ID: NCT05644041
View Trial